Compare YieldMax COIN Option Income Strategy ETF (CONY) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax COIN Option Income Strategy ETF vs State Street SPDR S&P Biotech ETF — how do they compare? YieldMax COIN Option Income Strategy ETF trades at $18.11, while State Street SPDR S&P Biotech ETF trades at $159.14. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, YieldMax COIN Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| CONY | XBI | |
|---|---|---|
Sector | Income / Options Overlay | Broad Market / Factor |
52-Week High | $76.50 | $164.28 |
52-Week Low | $17.80 | $86.92 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CONY trades at $18.11, up 0.22% on the day, with a bearish technical signal driven by moving averages. The ETF shows no available valuation or profitability ratios, and recent news highlights weekly dividend distributions but also concerns over shareholder losses and declining value despite high yields. Technical indicators show RSI near oversold levels at 29.18, suggesting potential for a rebound, while resistance sits at $19.
The outlook remains cautious due to bearish technicals and negative media sentiment questioning sustainability. Risks include reliance on options income and market volatility. Analyst coverage is limited, with no consensus ratings or price targets available, indicating uncertainty for investors.
XBI trades at $158.81, up 0.49% today, with a bullish technical signal supported by moving averages. The ETF shows strong momentum with a 17% monthly gain and 75% annual return, driven by biotech sector strength. Analyst coverage is limited to one hold rating, while recent news highlights institutional buying interest and positive sector developments including M&A activity and drug trial successes.
The outlook remains positive given biotech's breakout from multi-year bear markets, though elevated volatility and policy risks persist. Key opportunities include AI-driven drug discovery and sustained M&A momentum, while risks involve sector-specific volatility and regulatory uncertainty. The ETF's equal-weight approach provides diversified exposure to biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About YieldMax COIN Option Income Strategy ETF
CONY is an actively managed ETF that seeks to generate weekly income by selling call options on Coinbase (COIN) stock. It aims to provide high yield while maintaining exposure to the price movements of the crypto exchange.
Read more on CONY →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
